Illumina, Inc.
Illumina Announces Preliminary Financial Results for Q4 and FY 2025
Summary
On January 13, 2026, Illumina, Inc. announced preliminary unaudited financial results for the fourth quarter and fiscal year 2025, revealing revenue of approximately $1.155 billion for Q4 2025, up 5% year-over-year, and $4.34 billion for FY 2025, flat compared to 2024. The company reported GAAP diluted EPS of $2.14 to $2.17 for Q4 2025 and $5.42 to $5.45 for FY 2025. Non-GAAP diluted EPS was $1.27 to $1.30 for Q4 2025 and $4.76 to $4.79 for FY 2025. These preliminary results are subject to adjustment and the company expects to report full results on February 5, 2026.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement